{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T17:24:19Z","timestamp":1784136259128,"version":"3.55.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2016,11,10]],"date-time":"2016-11-10T00:00:00Z","timestamp":1478736000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Department account fund"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1007\/s10147-016-1063-0","type":"journal-article","created":{"date-parts":[[2016,11,10]],"date-time":"2016-11-10T15:40:27Z","timestamp":1478792427000},"page":"244-249","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Incidence of hypophosphatemia in advanced cancer patients: a recent report from a single institution"],"prefix":"10.1007","volume":"22","author":[{"given":"Taichi","family":"Yoshida","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daiki","family":"Taguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Fukuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiro","family":"Shimazu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsunori","family":"Murata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3581-3506","authenticated-orcid":false,"given":"Hiroyuki","family":"Shibata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,11,10]]},"reference":[{"key":"1063_CR1","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/S0140-6736(14)62038-9","volume":"385","author":"C Allemani","year":"2015","unstructured":"Allemani C, Allemani C, Weir HK et al (2015) CONCORD Working Group. Global surveillance of cancer survival 1995\u20132009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2). Lancet 385:977\u20131010","journal-title":"Lancet"},{"key":"1063_CR2","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1093\/annonc\/mdp533","volume":"21","author":"S Welch","year":"2010","unstructured":"Welch S, Spithoff K, Rumble RB et al (2010) Bevacizumab combined with chemotherapy for patients with advanced colorectal cancer: a systematic review. Ann Oncol 21:1152\u20131162","journal-title":"Ann Oncol"},{"key":"1063_CR3","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1200\/JCO.2009.23.7537","volume":"28","author":"JL Spratlin","year":"2010","unstructured":"Spratlin JL, Cohen RB, Eadens M et al (2010) Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. J Clin Oncol 28:780\u2013787","journal-title":"J Clin Oncol"},{"key":"1063_CR4","first-page":"21","volume":"20","author":"A Grothey","year":"2006","unstructured":"Grothey A (2006) Recognizing and managing toxicities of molecular targeted therapies for colorectal cancer. Oncology 20:21\u201328","journal-title":"Oncology"},{"key":"1063_CR5","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1093\/annonc\/mdv244","volume":"26","author":"B McLellan","year":"2015","unstructured":"McLellan B, Ciardiello F, Lacouture ME et al (2015) Regorafenib-associated hand-foot skin reaction: practical advice on diagnosis, prevention, and management. Ann Oncol 26:2017\u20132026","journal-title":"Ann Oncol"},{"key":"1063_CR6","doi-asserted-by":"crossref","first-page":"3082","DOI":"10.1016\/j.ejca.2012.08.002","volume":"48","author":"A Lipton","year":"2012","unstructured":"Lipton A, Fizazi K, Stopeck AT et al (2012) Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. Eur J Cancer 48:3082\u20133092","journal-title":"Eur J Cancer"},{"key":"1063_CR7","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/0002-9343(84)90112-8","volume":"77","author":"EA Ryan","year":"1984","unstructured":"Ryan EA, Reiss E (1984) Oncogenous osteomalacia. Review of the world literature of 42 cases and report of two new cases. Am J Med 77:501\u2013512","journal-title":"Am J Med"},{"key":"1063_CR8","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1056\/NEJMoa051140","volume":"354","author":"E Berman","year":"2006","unstructured":"Berman E, Nicolaides M, Maki RG et al (2006) Altered bone and mineral metabolism in patients receiving imatinib mesylate. N Engl J Med 354:2006\u20132013","journal-title":"N Engl J Med"},{"key":"1063_CR9","unstructured":"Package insert 1; package insert p 10. Available via http:\/\/packageinserts.bms.com\/pi\/pi_sprycel.pdf . Accessed 10 Nov 2016"},{"key":"1063_CR10","unstructured":"Package insert 2; package insert p 29. Available via https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/021938s13s17s18lbl.pdf#search='Sunitinib%2C+package' . Accessed 10 Nov 2016"},{"key":"1063_CR11","unstructured":"Package insert 3. In: US Food and Drug Administration. Tefinlar. Highlights of prescribing information, p 17. Available via http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/202806s002lbl.pdf#search='Dabrafenib%2C+Package+insert+2' . Accessed 10 Nov 2016"},{"key":"1063_CR12","first-page":"743","volume-title":"Oxford textbook of endocrinology and diabetes","author":"MP Whyte","year":"2011","unstructured":"Whyte MP, Liberman UA (2011) Rickets and osteomalacia (acquired and heritable forms) and skeletal dysplasias. In: Wass J, Stewart PM (eds) Oxford textbook of endocrinology and diabetes, 2nd edn. Oxford University Press, New York, pp 743\u2013744","edition":"2"},{"key":"1063_CR13","doi-asserted-by":"crossref","first-page":"R53","DOI":"10.1530\/ERC-11-0006","volume":"18","author":"WH Chong","year":"2011","unstructured":"Chong WH, Molinolo AA, Chen CC et al (2011) Tumor-induced osteomalacia. Endocr Relat Cancer 18:R53\u201377","journal-title":"Endocr Relat Cancer"},{"key":"1063_CR14","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1359\/jbmr.2002.17.6.1102","volume":"17","author":"SM Jan DeBeur","year":"2002","unstructured":"Jan DeBeur SM, Finnegan RB, Vassiliadis J et al (2002) Tumors associated with oncogenic osteomalacia express genes important in bone and mineral metabolism. J Bone Miner Res 17:1102\u20131110","journal-title":"J Bone Miner Res"},{"key":"1063_CR15","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1053\/j.ackd.2013.05.005","volume":"21","author":"MH Rosner","year":"2014","unstructured":"Rosner MH, Dalkin AC (2014) Electrolyte disorders associated with cancer. Adv Chronic Kidney Dis 21:7\u201317","journal-title":"Adv Chronic Kidney Dis"},{"key":"1063_CR16","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1038\/nature05315","volume":"444","author":"I Urakawa","year":"2006","unstructured":"Urakawa I, Yamazaki Y, Shimada T et al (2006) Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 444:770\u2013774","journal-title":"Nature"},{"issue":"Pt 1","key":"1063_CR17","first-page":"37","volume":"36","author":"JM Guy","year":"1999","unstructured":"Guy JM, Stewart MF, Olukoga A et al (1999) Hypophosphataemia in general practice patients. Ann Clin Biochem 36(Pt 1):37\u201342","journal-title":"Ann Clin Biochem"},{"key":"1063_CR18","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1007\/s00134-013-2970-4","volume":"39","author":"A Bech","year":"2013","unstructured":"Bech A, Blans M, Telting D et al (2013) Incidence and etiology of renal phosphate loss in patients with hypophosphatemia in the intensive care unit. Intensive Care Med 39:1785\u20131791","journal-title":"Intensive Care Med"},{"key":"1063_CR19","first-page":"2365","volume-title":"Harrison\u2019s principles of internal medicine","author":"FR Bringhurst","year":"2008","unstructured":"Bringhurst FR, Demay MB, Krane SM et al (2008) Bone and mineral metabolism in health and disease. In: Fauci AS et al (eds) Harrison\u2019s principles of internal medicine, 17th edn. Mac GrawHill, New York, pp 2365\u20132377","edition":"17"},{"key":"1063_CR20","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/S0899-9007(97)85089-7","volume":"12","author":"CR Paterson","year":"1996","unstructured":"Paterson CR (1996) Hypophosphataemia: a dangerous disorder. Nutrition 12:540\u2013541","journal-title":"Nutrition"},{"key":"1063_CR21","doi-asserted-by":"crossref","first-page":"346","DOI":"10.2337\/diab.30.4.346","volume":"30","author":"N Kono","year":"1981","unstructured":"Kono N, Kuwajima M, Tarui S (1981) Alteration of glycolytic intermediary metabolism in erythrocytes during diabetic ketoacidosis and its recovery phase. Diabetes 30:346\u2013353","journal-title":"Diabetes"},{"key":"1063_CR22","first-page":"45","volume":"9","author":"N Brautbar","year":"1983","unstructured":"Brautbar N, Leibovici H, Massry SG (1983) On the mechanism of hypophosphatemia during acute hyperventilation: evidence for increased muscle glycolysis. Miner Electrolyte Metab 9:45\u201350","journal-title":"Miner Electrolyte Metab"},{"key":"1063_CR23","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1001\/archinte.1980.00330220075027","volume":"140","author":"KW Zamkoff","year":"1980","unstructured":"Zamkoff KW, Kirshner JJ (1980) Marked hypophosphatemia associated with acute myelomonocytic leukemia. Indirect evidence of phosphorus uptake by leukemic cells. Arch Intern Med 140:1523\u20131524","journal-title":"Arch Intern Med"},{"key":"1063_CR24","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/BF00390471","volume":"108","author":"J Perek","year":"1984","unstructured":"Perek J, Mittelman M, Gafter U et al (1984) Hypophosphatemia accompanying blastic crisis in a patient with malignant lymphoma. J Cancer Res Clin Oncol 108:351\u2013353","journal-title":"J Cancer Res Clin Oncol"},{"key":"1063_CR25","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/j.0954-6820.1986.tb08979.x","volume":"Suppl 714","author":"SE Kjeldsen","year":"1986","unstructured":"Kjeldsen SE, Eide I, Os I et al (1986) Serum phosphate and sympathetic tone in mild essential hypertension. Acta Med Scand Suppl 714:119\u2013123","journal-title":"Acta Med Scand"},{"key":"1063_CR26","doi-asserted-by":"crossref","first-page":"941","DOI":"10.7326\/0003-4819-89-6-941","volume":"89","author":"RD Lentz","year":"1978","unstructured":"Lentz RD, Brown DM, Kjellstrand CM (1978) Treatment of severe hypophosphatemia. Ann Intern Med 89:941\u2013944","journal-title":"Ann Intern Med"},{"key":"1063_CR27","first-page":"144","volume":"40","author":"MH Alsumrain","year":"2010","unstructured":"Alsumrain MH, Jawad SA, Imran NB et al (2010) Association of hypophosphatemia with failure-to-wean from mechanical ventilation. Ann Clin Lab Sci 40:144\u2013148","journal-title":"Ann Clin Lab Sci"},{"key":"1063_CR28","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.2146\/ajhp040300","volume":"62","author":"MD Kraft","year":"2005","unstructured":"Kraft MD, Btaiche IF, Sacks GS et al (2005) Treatment of electrolyte disorders in adult patients in the intensive care unit. Am J Health Syst Pharm 62:1663\u20131682","journal-title":"Am J Health Syst Pharm"},{"key":"1063_CR29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00005792-200001000-00001","volume":"79","author":"R Subramanian","year":"2000","unstructured":"Subramanian R, Khardori R (2000) Severe hypophosphatemia. Pathophysiologic implications, clinical presentations, and treatment. Medicine (Baltimore) 79:1\u20138","journal-title":"Medicine (Baltimore)"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-016-1063-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10147-016-1063-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-016-1063-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T14:06:24Z","timestamp":1718892384000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10147-016-1063-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,10]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["1063"],"URL":"https:\/\/doi.org\/10.1007\/s10147-016-1063-0","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,10]]}}}